NCT06356519View on ClinicalTrials.gov

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

RecruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

April 1, 2025

Conditions

Breast Cancer

Interventions

DRUG

Sacituzumab Govitecan

Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER